Antibody Persistence, and Safety and Tolerability of a Booster Dose of the Meningococcal B Vaccine After the Completion of the Vaccination Course in Study V72_28

Inclusion criteria

• ✓. Healthy infants and children according to the following age groups:
• ✓. Healthy subjects from 35 to 47 months of age, (only applicable to group K) (The age window is defined as the first day the subject turns 35 months of age up to the day before the subject turns 48 months of age),
• ✓. Healthy subjects 4 to 7 years of age (only applicable to group L) (The age window is defined as the first day the subject turns 4 years of age up to the day before the subject turns 8 years of age).
• ✓. Healthy subjects 8 to 12 years of age (only applicable to group M) (The age window is defined as the first day the subject turns 8 years of age up to the day before the subject turns 13 years of age).
• ✓. for whom a parent/legal guardian has given written informed consent after the nature of the study has been explained;
• ✓. for whom a parent/legal guardian confirmed availability for the visit scheduled in the study;
• ✓. in good health as determined by medical history, physical examination, clinical judgment of the investigator.
• ✓. for whom a parent/legal guardian has given written informed consent after the nature of the study has been explained;

Exclusion criteria